Skip To Main Content
Razelle Kurzrock on Muck Rack

Razelle Kurzrock

San Diego
As seen in: British Journal of Cancer, Color Research & Application, Nature, Wiley Online Library, The Oncologist, MDPI, Genome Medicine, JAMA Oncology, The New England Journal of Medicine, Medscape and
Momx7 (4 children; 3 dogs); wife; Precision/Rare diseases; MCW AD; CMO WIN; physician, not provider; Board CureMetrix/CureMatch (cofounder); opinions mine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Razelle

Contact Razelle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Anaplastic thyroid cancer: review of precision therapy options and advances

|
By Noor Mohammed Khalid, Razelle Kurzrock, Shumei Kato
| Nature Verified
Abstract Anaplastic thyroid cancer (ATC) is a rare and aggressive tumor with a historical median survival of less than six months. Most patients have advanced disease at the time of diagnosis. Traditional cytotoxic chemotherapy has not shown survival benefits. Molecular testing and next-generation sequencing are used to identify specific targets for patients with ATC. If positive for BRAF V600E mutation, patients can be treated with BRAF/MEK inhibitors.
Open in Who Shared Issue with article?

Beyond one gene, one target: Next-generation precision oncology

|
By Vivek Subbiah, Razelle Kurzrock
| Cell Press Verified
Keywords precision biomarkers cancer targeted therapy genomics Get full text access Log in, subscribe or purchase for full access. References 1. Verkerk, K. ... Prospective evaluation of genomics-guided off-label treatment Nature. 2026; 653:558-566 2. Zeverijn, L.J. ... The innate immune landscape of dMMR/MSI cancers predicts the outcome of nivolumab treatment: results from the drug rediscovery protocol Clin. Cancer Res. 2024; 30:4339-4351 3. Liu, R. ...
Open in Who Shared Issue with article?

Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy

|
By Yu Fujiwara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna M. Lee, Taylor Jensen, Paul DePietro, RJ Seager, Sadakatsu Ikeda, Razelle Kurzrock
| Nature Verified
Abstract Tertiary lymphoid structures (TLSs) facilitate tumor microenvironment immune interactions. While TLSs and their associated gene signatures correlate with better response to immune checkpoint inhibitors (ICIs), the complex transcriptomic interplay/co-regulation among these factors remains under investigation. We analyzed correlations between survival and transcriptome expression (35 immunoregulatory factors associated with B/T cells and TLSs) in 217 patients with ICI-treated solid tumors.
Open in Who Shared Issue with article?
See all 59 articles